|Mr. David J. Marguglio||Co-Founder, Interim CFO. Pres & COO||526.35k||N/A||1970|
|Dr. Ebrahim Versi M.D., Ph.D.||CEO & Chair of the Board||N/A||N/A||1953|
|Ms. Jennifer C. Suski||Sr. Director of Marketing||N/A||N/A||N/A|
|Mr. Eddie Wabern Glover||Chief Exec. Officer of US Compounding Inc||N/A||N/A||1950|
|Mr. Robert B. Rothermel||Consultant||N/A||N/A||1944|
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.
Adamis Pharmaceuticals Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.